Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Engineering PTEN-L for Cell-Mediated Delivery.

Lavictoire SJ, Gont A, Julian LM, Stanford WL, Vlasschaert C, Gray DA, Jomaa D, Lorimer IAJ.

Mol Ther Methods Clin Dev. 2017 Nov 21;9:12-22. doi: 10.1016/j.omtm.2017.11.006. eCollection 2018 Jun 15.

2.

Induction of senescence in primary glioblastoma cells by serum and TGFβ.

Kumar R, Gont A, Perkins TJ, Hanson JEL, Lorimer IAJ.

Sci Rep. 2017 May 19;7(1):2156. doi: 10.1038/s41598-017-02380-1.

3.

PREX1 integrates G protein-coupled receptor and phosphoinositide 3-kinase signaling to promote glioblastoma invasion.

Gont A, Daneshmand M, Woulfe J, Lavictoire SJ, Lorimer IA.

Oncotarget. 2017 Jan 31;8(5):8559-8573. doi: 10.18632/oncotarget.14348.

4.

Control of glioblastoma tumorigenesis by feed-forward cytokine signaling.

Jahani-Asl A, Yin H, Soleimani VD, Haque T, Luchman HA, Chang NC, Sincennes MC, Puram SV, Scott AM, Lorimer IA, Perkins TJ, Ligon KL, Weiss S, Rudnicki MA, Bonni A.

Nat Neurosci. 2016 Jun;19(6):798-806. doi: 10.1038/nn.4295. Epub 2016 Apr 25.

5.

PKCι depletion initiates mitotic slippage-induced senescence in glioblastoma.

Restall IJ, Parolin DA, Daneshmand M, Hanson JE, Simard MA, Fitzpatrick ME, Kumar R, Lavictoire SJ, Lorimer IA.

Cell Cycle. 2015;14(18):2938-48. doi: 10.1080/15384101.2015.1071744.

6.

Atypical PKCι as target for glioblastoma therapy.

Lorimer IA.

Curr Cancer Drug Targets. 2015;15(2):136-44. Review.

PMID:
25643257
7.

Inhibition of glioblastoma malignancy by Lgl1.

Gont A, Hanson JE, Lavictoire SJ, Daneshmand M, Nicholas G, Woulfe J, Kassam A, Da Silva VF, Lorimer IA.

Oncotarget. 2014 Nov 30;5(22):11541-51.

8.

PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.

Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, Lee U, Haq R, Virk S, Tu D, Lorimer IA; NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group.

Clin Cancer Res. 2014 Feb 1;20(3):744-53. doi: 10.1158/1078-0432.CCR-13-0606. Epub 2013 Nov 11.

9.

Loss of PDCD4 contributes to enhanced chemoresistance in Glioblastoma multiforme through de-repression of Bcl-xL translation.

Liwak U, Jordan LE, Von-Holt SD, Singh P, Hanson JE, Lorimer IA, Roncaroli F, Holcik M.

Oncotarget. 2013 Sep;4(9):1365-72.

10.

PTEN loss represses glioblastoma tumor initiating cell differentiation via inactivation of Lgl1.

Gont A, Hanson JE, Lavictoire SJ, Parolin DA, Daneshmand M, Restall IJ, Soucie M, Nicholas G, Woulfe J, Kassam A, Da Silva VF, Lorimer IA.

Oncotarget. 2013 Aug;4(8):1266-79.

11.

Detection of PIK3CA Mutations in Breast Cancer Bone Metastases.

Daneshmand M, Hanson JE, Nabavi M, Hilton JF, Vandermeer L, Kanji F, Dent SF, Clemons M, Lorimer IA.

ISRN Oncol. 2012;2012:492578. doi: 10.5402/2012/492578. Epub 2012 Aug 30.

12.

Repression of cancer cell senescence by PKCι.

Paget JA, Restall IJ, Daneshmand M, Mersereau JA, Simard MA, Parolin DA, Lavictoire SJ, Amin MS, Islam S, Lorimer IA.

Oncogene. 2012 Aug 2;31(31):3584-96. doi: 10.1038/onc.2011.524. Epub 2011 Nov 28.

PMID:
22120720
13.

Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease.

Vickers MM, Bar J, Gorn-Hondermann I, Yarom N, Daneshmand M, Hanson JE, Addison CL, Asmis TR, Jonker DJ, Maroun J, Lorimer IA, Goss GD, Dimitroulakos J.

Clin Exp Metastasis. 2012 Feb;29(2):123-32. doi: 10.1007/s10585-011-9435-3. Epub 2011 Nov 26.

PMID:
22120473
14.

Modelling the role of the Hsp70/Hsp90 system in the maintenance of protein homeostasis.

Proctor CJ, Lorimer IA.

PLoS One. 2011;6(7):e22038. doi: 10.1371/journal.pone.0022038. Epub 2011 Jul 14.

15.

Coordination of glioblastoma cell motility by PKCι.

Baldwin RM, Barrett GM, Parolin DA, Gillies JK, Paget JA, Lavictoire SJ, Gray DA, Lorimer IA.

Mol Cancer. 2010 Sep 3;9:233. doi: 10.1186/1476-4598-9-233.

16.

Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX.

Poulin KL, Lanthier RM, Smith AC, Christou C, Risco Quiroz M, Powell KL, O'Meara RW, Kothary R, Lorimer IA, Parks RJ.

J Virol. 2010 Oct;84(19):10074-86. doi: 10.1128/JVI.02665-09. Epub 2010 Jul 14.

17.

Induction of premature senescence by hsp90 inhibition in small cell lung cancer.

Restall IJ, Lorimer IA.

PLoS One. 2010 Jun 11;5(6):e11076. doi: 10.1371/journal.pone.0011076.

18.

Regulation of p27Kip1 by miRNA 221/222 in glioblastoma.

Lorimer IA.

Cell Cycle. 2009 Sep 1;8(17):2685. Epub 2009 Sep 1. No abstract available.

PMID:
19690454
19.

Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.

Cemeus C, Zhao TT, Barrett GM, Lorimer IA, Dimitroulakos J.

J Neurooncol. 2008 Oct;90(1):9-17. doi: 10.1007/s11060-008-9627-0. Epub 2008 Jun 20.

PMID:
18566746
20.

Activation of p38MAPK contributes to expanded polyglutamine-induced cytotoxicity.

Tsirigotis M, Baldwin RM, Tang MY, Lorimer IA, Gray DA.

PLoS One. 2008 May 7;3(5):e2130. doi: 10.1371/journal.pone.0002130.

21.

Regulation of glioblastoma cell invasion by PKC iota and RhoB.

Baldwin RM, Parolin DA, Lorimer IA.

Oncogene. 2008 Jun 5;27(25):3587-95. doi: 10.1038/sj.onc.1211027. Epub 2008 Jan 21.

PMID:
18212741
22.

Regulation of p27Kip1 by miRNA 221/222 in glioblastoma.

Gillies JK, Lorimer IA.

Cell Cycle. 2007 Aug 15;6(16):2005-9. Epub 2007 May 31.

PMID:
17721077
23.

Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway.

Dimitroulakos J, Lorimer IA, Goss G.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4426s-4431s. Review.

24.

Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase Ciota-mediated attenuation of p38 MAP kinase signaling.

Baldwin RM, Garratt-Lalonde M, Parolin DA, Krzyzanowski PM, Andrade MA, Lorimer IA.

Oncogene. 2006 May 11;25(20):2909-19.

PMID:
16331246
25.

Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.

Mantha AJ, Hanson JE, Goss G, Lagarde AE, Lorimer IA, Dimitroulakos J.

Clin Cancer Res. 2005 Mar 15;11(6):2398-407.

26.

A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer.

Mackenzie MJ, Hirte HW, Glenwood G, Jean M, Goel R, Major PP, Miller WH Jr, Panasci L, Lorimer IA, Batist G, Matthews S, Douglas L, Seymour L.

Invest New Drugs. 2005 Mar;23(2):165-70.

PMID:
15744593
27.

A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.

Goss G, Hirte H, Miller WH Jr, Lorimer IA, Stewart D, Batist G, Parolin DA, Hanna P, Stafford S, Friedmann J, Walsh W, Mathews S, Douglas L, Seymour LK.

Invest New Drugs. 2005 Mar;23(2):147-55.

PMID:
15744591
28.

Rescue and propagation of fully retargeted oncolytic measles viruses.

Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, James CD, Russell SJ.

Nat Biotechnol. 2005 Feb;23(2):209-14. Epub 2005 Jan 30.

PMID:
15685166
29.

Helper-dependent adenoviral vectors containing modified fiber for improved transduction of developing and mature muscle cells.

Bramson JL, Grinshtein N, Meulenbroek RA, Lunde J, Kottachchi D, Lorimer IA, Jasmin BJ, Parks RJ.

Hum Gene Ther. 2004 Feb;15(2):179-88.

PMID:
14975190
30.

Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.

Gunaratnam L, Morley M, Franovic A, de Paulsen N, Mekhail K, Parolin DA, Nakamura E, Lorimer IA, Lee S.

J Biol Chem. 2003 Nov 7;278(45):44966-74. Epub 2003 Aug 27.

31.

Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells.

Mantha AJ, McFee KE, Niknejad N, Goss G, Lorimer IA, Dimitroulakos J.

J Cancer Res Clin Oncol. 2003 Nov;129(11):631-41. Epub 2003 Aug 26.

PMID:
12942316
32.

A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.

Daneshmand M, Parolin DA, Hirte HW, Major P, Goss G, Stewart D, Batist G, Miller WH Jr, Matthews S, Seymour L, Lorimer IA.

Clin Cancer Res. 2003 Jul;9(7):2457-64.

33.

Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII.

Lavictoire SJ, Parolin DA, Klimowicz AC, Kelly JF, Lorimer IA.

J Biol Chem. 2003 Feb 14;278(7):5292-9. Epub 2002 Dec 5.

34.

Mutant epidermal growth factor receptors as targets for cancer therapy.

Lorimer IA.

Curr Cancer Drug Targets. 2002 Jun;2(2):91-102. Review.

PMID:
12188912
35.

Induction of apoptosis in glioblastoma cells by an atypical protein kinase C pseudosubstrate peptide.

Lorimer IA, Parolin DA, Lavictoire SJ.

Anticancer Res. 2002 Mar-Apr;22(2A):623-31.

PMID:
12014630
36.

Antibody recognition of a conformational epitope in a peptide antigen: Fv-peptide complex of an antibody fragment specific for the mutant EGF receptor, EGFRvIII.

Landry RC, Klimowicz AC, Lavictoire SJ, Borisova S, Kottachchi DT, Lorimer IA, Evans SV.

J Mol Biol. 2001 May 18;308(5):883-93.

PMID:
11352579
37.

Activation of extracellular-regulated kinases by normal and mutant EGF receptors.

Lorimer IA, Lavictoire SJ.

Biochim Biophys Acta. 2001 Feb 5;1538(1):1-9.

39.

Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1.

Archer GE, Sampson JH, Lorimer IA, McLendon RE, Kuan CT, Friedman AH, Friedman HS, Pastan IH, Bigner DD.

Clin Cancer Res. 1999 Sep;5(9):2646-52.

40.

125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.

Kuan CT, Reist CJ, Foulon CF, Lorimer IA, Archer G, Pegram CN, Pastan I, Zalutsky MR, Bigner DD.

Clin Cancer Res. 1999 Jun;5(6):1539-49.

41.

Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display.

Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I.

Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14815-20.

42.

Random recombination of antibody single chain Fv sequences after fragmentation with DNaseI in the presence of Mn2+.

Lorimer IA, Pastan I.

Nucleic Acids Res. 1995 Aug 11;23(15):3067-8. No abstract available.

43.

Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.

Lorimer IA, Wikstrand CJ, Batra SK, Bigner DD, Pastan I.

Clin Cancer Res. 1995 Aug;1(8):859-64.

44.

Protein kinase A regulation of cAMP phosphodiesterase expression in rat skeletal myoblasts.

Kovala T, Lorimer IA, Brickenden AM, Ball EH, Sanwal BD.

J Biol Chem. 1994 Mar 25;269(12):8680-5.

45.
46.
47.
48.

Supplemental Content

Loading ...
Support Center